Ignite Creation Date:
2025-12-24 @ 3:54 PM
Ignite Modification Date:
2026-02-18 @ 2:40 AM
Study NCT ID:
NCT01845792
Status:
TERMINATED
Last Update Posted:
2018-06-04
First Post:
2013-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011471', 'term': 'Prostatic Neoplasms'}], 'ancestors': [{'id': 'D005834', 'term': 'Genital Neoplasms, Male'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D005832', 'term': 'Genital Diseases, Male'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D011469', 'term': 'Prostatic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C552428', 'term': 'cabazitaxel'}, {'id': 'D000069501', 'term': 'Abiraterone Acetate'}], 'ancestors': [{'id': 'D000736', 'term': 'Androstenes'}, {'id': 'D000731', 'term': 'Androstanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'elaine.lam@ucdenver.edu', 'phone': '7208480273', 'title': 'Elaine Lam, MD', 'organization': 'University of Colorado Cancer Center'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Patients were on study between 3 to 14 months. Adverse event data were collected throughout study.', 'description': 'Due to early closure and small number of patients enrolled, no statistics or firm conclusions can be made. The 5 patients treated in the combination arm were treated with the standard dosing of both abiraterone acetate and cabazitaxel.', 'eventGroups': [{'id': 'EG000', 'title': 'Cabazitaxel With Abiraterone Acetate', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.\n\nCabazitaxel with Abiraterone Acetate: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 0, 'seriousNumAtRisk': 5, 'deathsNumAffected': 5, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Cabazitaxel Alone', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks\n\nCabazitaxel: Cabazitaxel intravenously every 3 weeks', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 2, 'otherNumAffected': 0, 'seriousNumAtRisk': 2, 'deathsNumAffected': 2, 'seriousNumAffected': 0}], 'seriousEvents': [{'term': 'Neutropenia', 'notes': 'Grade 4 Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Progression-Free Survival', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cabazitaxel With Abiraterone Acetate', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.\n\nCabazitaxel with Abiraterone Acetate: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.'}, {'id': 'OG001', 'title': 'Cabazitaxel Alone', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks\n\nCabazitaxel: Cabazitaxel intravenously every 3 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 months', 'description': 'Progression-free survival at 3 months.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Due to early closure of the study and the low number of patients enrolled, no statistics or firm conclusions can be made.'}, {'type': 'SECONDARY', 'title': 'PSA Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cabazitaxel With Abiraterone Acetate', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.\n\nCabazitaxel with Abiraterone Acetate: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.'}, {'id': 'OG001', 'title': 'Cabazitaxel Alone', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks\n\nCabazitaxel: Cabazitaxel intravenously every 3 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '2 years', 'description': 'Prostate specific antigen (PSA) decline by 50% or more from baseline.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Cabazitaxel With Abiraterone Acetate', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.\n\nCabazitaxel with Abiraterone Acetate: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.'}, {'id': 'FG001', 'title': 'Cabazitaxel Alone', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks\n\nCabazitaxel: Cabazitaxel intravenously every 3 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Cabazitaxel With Abiraterone Acetate', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.\n\nCabazitaxel with Abiraterone Acetate: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.'}, {'id': 'BG001', 'title': 'Cabazitaxel Alone', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks\n\nCabazitaxel: Cabazitaxel intravenously every 3 weeks'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Prior Docetaxel AND Abiraterone', 'classes': [{'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-06-28', 'size': 1927105, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2018-04-11T11:30', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 7}}, 'statusModule': {'whyStopped': 'Low accrual', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2013-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-05', 'completionDateStruct': {'date': '2017-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-05-31', 'studyFirstSubmitDate': '2013-04-29', 'resultsFirstSubmitDate': '2018-04-11', 'studyFirstSubmitQcDate': '2013-05-02', 'lastUpdatePostDateStruct': {'date': '2018-06-04', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-05-31', 'studyFirstPostDateStruct': {'date': '2013-05-03', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-06-04', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-Free Survival', 'timeFrame': '3 months', 'description': 'Progression-free survival at 3 months.'}], 'secondaryOutcomes': [{'measure': 'PSA Response', 'timeFrame': '2 years', 'description': 'Prostate specific antigen (PSA) decline by 50% or more from baseline.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Metastatic Castrate Resistant Prostate Cancer'], 'conditions': ['Prostate Cancer']}, 'descriptionModule': {'briefSummary': 'Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments. If they join this study they will receive a new combination of drugs that are used to treat prostate cancer.', 'detailedDescription': 'Abiraterone acetate and cabazitaxel have been approved by the United States Food and Drug Administration (FDA) to treat prostate cancer that has spread to other parts of the body such as the lymph nodes or bone. These drugs are approved individually for use when the cancer has become resistant to other treatments, including chemotherapy with docetaxel. The combination of these two drugs has not been evaluated, so the research team will study the safety and effectiveness of the combination.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '95 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Written informed consent has been obtained.\n* Adults over 18 years of age.\n* Histologically or cytologically proven adenocarcinoma of the prostate.\n* Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on CT scan and/or bone scan\n* Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:\n\n 1. Increase in measurable disease per RECIST 1.1,\n 2. Appearance of new lesions on bone scan consistent with progressive prostate cancer (\\>2 new lesions on bone scans if this is the only measure of PD),\n 3. rising PSA defined as 2 sequential increases above a previous lowest reference value.\n\n * Each value must be obtained at least 1 week apart.\n* PSA at least 2 ng/mL\n* Received prior docetaxel chemotherapy\n* Received prior abiraterone acetate, but not within the 3 months prior to study drug dosing.\n* Testosterone level \\<50 ng/mL. Patients receiving Leutinizing Hormone Releasing Hormone (LHRH) agonists or antagonists must be continued to maintain castrate levels of testosterone while on study.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Adequate hematologic function:\n\n 1. platelet \\>100, 000/uL;\n 2. neutrophil count of \\>1500 cell/mm3;\n 3. hemoglobin \\>9.0 g/dL)\n* Adequate renal function (Creatinine clearance \\> 50 mL/min)\n* Adequate potassium level (\\> 3.5 mEq/dL)\n* Adequate hepatic function\n\n 1. bilirubin \\< 1.5 X upper limit of normal (ULN),\n 2. alanine aminotransferase (ALT) \\< 1.5 X ULN,\n 3. aspartate aminotransferase (AST) \\< 1.5 X ULN.\n 4. serum albumin of ≥ 3.0 g/dL.\n* Controlled blood pressure, defined as blood pressure ≤ 140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged)\n* Must be able to take oral medication without crushing, dissolving or chewing tablets\n* Willing to take abiraterone acetate on empty stomach;\n\n (1) no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken.\n* Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.\n* Written authorization for use and release of health and research study information has been obtained.\n* Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last dose of abiraterone acetate.\n\nExclusion Criteria:\n\n* Surgery or radiation therapy within 2 weeks, or\n* Cytotoxic anti-cancer therapy within 3 weeks, or\n* Non-cytotoxic anti-cancer therapy within 2 weeks, or 5 half-lives (whichever is shorter) of Study Day 1.\n* Prior radiotherapy to ≥ 40% of bone marrow.\n* Prior treatment with Radium 223.\n* Use of an investigational therapeutic agent within 30 days.\n* Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents.\n* Prior treatment with cabazitaxel.\n* Known chronic infection with human immunodeficiency virus (HIV).\n* Known active, or symptomatic, brain metastasis.\n* Blood pressure \\>140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged).\n* History of autoimmune disorder requiring daily corticosteroid therapy of greater than prednisone 10mg daily, or its equivalent.\n* Baseline peripheral edema \\> grade 3.\n* Pre-existing diarrhea uncontrolled with supportive care;\n* Prior hemorrhagic diarrhea due to ulcerative colitis, inflammatory bowel disease or other cause;\n* Active, uncontrolled peptic ulcer disease even in the setting of proton-pump inhibitor or Histamine2-blocker use.\n* Pre-existing peripheral neuropathy grade \\> 2.\n* Documented hypersensitivity (CTCAE grade \\> 2) to any drug containing polysorbate 80.\n* Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients.\n* Contraindications to steroid use.\n* Need for medications that strongly induce or inhibit cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2D6 (CYP2D6) activity. (see section 7.2.3 for details)\n* Serious infection requiring parenteral antibiotics within 14 days of enrollment.\n* Poorly controlled diabetes (Hgb A1C \\>9).\n* Active or symptomatic viral hepatitis or Chronic liver disease, including Child-Pugh Class B and C liver disease.\n* History of pituitary or adrenal dysfunction.\n* Clinically significant heart disease as evidenced by:\n\n 1. myocardial infarction, or\n 2. arterial thrombotic events in the past 6 months,\n 3. severe or unstable angina, or\n 4. New York Heart Association Class III-IV heart disease, or\n 5. cardiac ejection fraction measurement of \\<50% at baseline.\n* Consumption of food or beverages containing grapefruit juice within 7 days of study drug dosing\n* Use of a first-generation anti-androgen such as:\n\n 1. bicalutamide within 6 weeks of study drug dosing, or\n 2. flutamide within 4 weeks of study dosing.\n* Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.'}, 'identificationModule': {'nctId': 'NCT01845792', 'briefTitle': 'Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer', 'organization': {'class': 'OTHER', 'fullName': 'University of Colorado, Denver'}, 'officialTitle': 'Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.', 'orgStudyIdInfo': {'id': '13-1489.cc'}, 'secondaryIdInfos': [{'id': 'NCI-2013-01356', 'type': 'OTHER', 'domain': 'National Cancer Institute'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cabazitaxel with Abiraterone Acetate', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.', 'interventionNames': ['Drug: Cabazitaxel with Abiraterone Acetate']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Cabazitaxel Alone', 'description': 'Cabazitaxel administered as a single intravenous dose every 3 weeks', 'interventionNames': ['Drug: Cabazitaxel']}], 'interventions': [{'name': 'Cabazitaxel with Abiraterone Acetate', 'type': 'DRUG', 'otherNames': ['Jevtana', 'Zytiga'], 'description': 'Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.', 'armGroupLabels': ['Cabazitaxel with Abiraterone Acetate']}, {'name': 'Cabazitaxel', 'type': 'DRUG', 'otherNames': ['Jevtana'], 'description': 'Cabazitaxel intravenously every 3 weeks', 'armGroupLabels': ['Cabazitaxel Alone']}]}, 'contactsLocationsModule': {'locations': [{'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado Cancer Center', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}], 'overallOfficials': [{'name': 'Elaine Lam, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Colorado, Denver'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Colorado, Denver', 'class': 'OTHER'}, 'collaborators': [{'name': 'Janssen Services, LLC', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}